Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: eflornithine
BRAND NAME: Vaniqa
DRUG CLASS AND MECHANISM: Eflornithine is the first topical drug (used on the skin) for the treatment of unwanted facial and chin hair. It does not remove the hair but rather slows its growth. The cells surrounding the base of each hair (called the hair follicle) undergo rapid growth and maturation as they transform into hairs. Certain proteins called polyamines are needed for this rapid cell growth and differentiation, and the production of these polyamines depends on the activity of an enzyme, ornithine decarboxylase (ODC). Eflornithine is believed to block ODC, slowing the growth and differentiation of the cells within the hair follicles. Eflornithine was approved by the FDA in July 2000.
GENERIC AVAILABLE: No
PREPARATIONS: Eflornithine is available as a 30 gram tube of cream at a concentration of 13.9%.
STORAGE: Eflornithine should be stored at room temperature, 15 C to 30 C (59 F to 86 F) and should not be frozen.
PRESCRIBED FOR: Eflornithine is used to slow hair growth on the face and chin in women ages 12 and older.
Almost 600 patients were studied who routinely had to remove facial hair at least twice weekly and had more than 5 hairs per square centimeter of skin. The re-growth of hair was evaluated 48 hours after patients shaved before, during, and at the end of treatment. The patients received either eflornithine cream or a placebo cream twice daily for 24 weeks. By the end of 24 weeks of treatment, 70% of eflornithine-treated patients had at least some reduction in the rate of hair growth compared with 41% of placebo-treated patients. Moreover, 35% of eflornithine-treated patients had a marked reduction in the rate of growth (only minimal darkening of facial skin due to re-growth of hair) compared to 9% of placebo-treated patients.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index